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Abstract. Epigenetic mechanisms of histone acetylation/
deacetylation play an important role in the regulation of 
gene expression associated with the cell cycle and apoptosis. 
Recently, sodium butyrate, a histone deacetylase (HDAC) 
inhibitor, has been shown to exhibit anticancer effects via 
differentiation and apoptosis of cancer cells. Sodium butyrate 
may be a potential anticancer chemotherapeutic drug; 
however, the precise mechanism underlying the anticancer 
effects of sodium butyrate has not been clearly elucidated. In 
the present study, we investigated the role of death-associated 
protein kinase (DAPK) on the apoptosis of human gastric 
cancer cells induced by sodium butyrate. We observed that 
sodium butyrate induced apoptosis in human gastric cancer 
cells. Treatment with the HDAC inhibitor sodium butyrate 
increased the expression of caspase-3 and DAPK1/2 genes 
but decreased the expression of Bcl-2 in human gastric cancer 
cells. The expression of DAPK3, p53 and p21 were not altered 
by sodium butyrate treatment. Analysis of the general expres-
sion patterns revealed that sodium butyrate increased the 
expression of DAPK1/2 but decreased the expression of FAK 
and induced changes in the proliferation of apoptosis-related 
genes in human gastric cancer cells. These data suggest that 
DAPK expression prompts apoptosis by reducing the FAK 
protein level in sodium butyrate-induced apoptosis of human 
gastric cancer cells.
Introduction
Histone deacetylase (HDAC) inhibitors represent a structur-
ally diverse group of compounds that inhibit the deacetylation 
of histones, permitting the chromatin scaffolding to assume a 
more relaxed, open conformation, which generally promotes 
gene transcription. HDAC inhibitors induce apoptosis in cancer 
cells through multiple mechanisms, and thus are emerging as a 
promising new therapeutic tool for the treatment of a variety of 
human cancers (7). Sodium butyrate (NaB), a short chain fatty 
acid, occurs naturally in the body and is synthesized through 
the acetyl-CoA-dependent catabolic oxidation of long chain 
saturated fatty acids (1,2). Sodium butyrate, acting as an HDAC 
inhibitor, is known to exhibit anticancer effects via differentia-
tion of carcinoma cells (3-6). NaB is a novel chemotherapeutic 
agent as it is able to activate a variety of anticancer mecha-
nisms, including cell cycle arrest and cellular differentiation 
(8-10). Sodium butyrate induces apoptosis, decreases Bcl-2 
transcription (11), increases TNF-related apoptosis-inducing 
ligand receptor 2 gene transcription to accelerate the death-
inducing signaling complex formation, activates caspase, and 
inhibits the mitochondrial membrane potential of cancer cells 
(12). These results suggest that NaB may represent a potential 
new class of anticancer agents with low toxicity; however, the 
mechanisms of action are not fully understood.
DAPK induces programmed cell death through various 
signaling pathways. FAK participates in signaling pathways 
involved in adhesion between cells and the extracellular 
matrix, including proteins such as fibronectin, laminin, actin, 
and fodrin. FAK is a survival protein that suppresses apoptosis 
and maintains cell suspended growth (26). In this study, we 
attempted to elucidate NaB-induced death-associated protein 
kinase expression and its association with human gastric 
cancer cell apoptosis.
Materials and methods
Cell culture and treatments. A total of nine human gastric 
cancer cell lines (AGS, Kato Ⅲ, MKN28, MKN45, MKN74, 
NCI-N87, SNU1, SNU16 and SNU638) were obtained from 
the Korean Cell Line Bank (Korea) and the American Type 
Culture Collection (Manassas, VA, USA). Cells were cultured 
in RPMI-1640 medium (Hyclone Laboratories, Inc., USA) 
containing 10% fetal bovine serum (Hyclone) and 1% peni-
cillin streptomycin sulfate (Hyclone) at 5% CO2, 37˚C, and 
95% humidity. Sodium butyrate, 5'-Aza-2-deoxycytidine 
(5'-Aza-dC), and trichostatin A were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Working concentrations were 
as follows: sodium butyrate (NaB), 2 µM; 5-Aza-dC, 2 µM; 
and trichostatin A, 200 nM.
Sodium butyrate-induced DAPK-mediated apoptosis 
 in human gastric cancer cells
HYUNSOO SHIN1,  YEO SONG LEE1,2  and  YONG CHAN LEE1,2
1Department of Internal Medicine, Institute of Gastroenterology, 2Brain Korea 21 Project for 
Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea
Received October 7, 2011;  Accepted November 21, 2011
DOI: 10.3892/or.2011.1585
Correspondence to:  Dr Yong Chan Lee, Department of Internal 
Medicine, Yonsei University College of Medicine, 134 Shinchon-
Dong, Seodaemun-Ku, Seoul 120-752, Republic of Korea
E-mail: leeyc@yuhs.ac
Key words: histone deacetylase inhibitor, sodium butyrate, death-
associated protein kinase
SHIN et al:  SODIUM BUTYRATE-INDUCED DAPK-MEDIATED APOPTOSIS1112
RNA isolation and reverse transcription polymerase chain 
reaction. Total RNA was prepared using TRIzol reagent 
(Invitrogen). The RNA was reverse transcribed using oligo 
(dT) primers and SuperscriptT™ Ⅱ reverse transcriptase 
(Invitrogen, Carlsbad, CA, USA). Primers used for PCR ampli-
fication of this cDNA were caspase-3: forward, 5'-GGC ATT 
GAG ACA GAC AGT GGT G-3' and reverse, 5'-GCA CAA 
AGC GAC TGG ATG AAC C-3'; Bcl-2: forward, 5'-GAG TAC 
CTG AAC CGG CAC CT-3' and reverse, 5'-CAG GGT GAT 
GCA AGC TCC CA-3'; DAPK1: forward, 5'-TCT ACC AGC 
CAC GGG ACT TC-3' and reverse, 5'-GCT GGC CTG TGA 
GTA GAC GT-3'; DAPK2: forward, 5'-GCA TCG TGT CCC 
TGT GCA AC-3' and reverse, 5'-GCT TTC CTC CTG GCG 
ATG TC-3'; DAPK3: forward, 5'-CCC AAC CCA CGA ATC 
AAG CTC-3' and reverse, 5'-GCT GAG ATG TTG GTG AGC 
GTC-3'; p21: forward, 5'-GTA CCC TTG TGC CTC GCT 
CA-3' and reverse, 5'-CCG GCG TTT GGA GTG GTA GA-3'; 
p53: forward, 5'-AGC GAT GGT CTG GCC CCT CCT-3' and 
reverse, 5'-CTC AGG CGG CTC ATA GGG CAC-3'; and 
β-actin: forward, 5'-TTG CCG ACA GGA TGC AGA AG-3' 
and reverse, 5'-AGG TGG ACA GCG AGG CCA GG-3'. PCR 
reactions were performed with the PCR Maxi kit (Intron, 
Sungnam, Korea). PCR reactions in the linear range of amplifi-
cation were analyzed by agarose gel electrophoresis and 
quantified by densitometry, if needed.
Western blot analysis. Prepared cells were harvested after 
washing with PBS. Collected cells were lysed with buffer 
[50 mM Tris-Cl (pH 7.5), 150 mM NaCl, 1 mM EDTA (pH 8.0), 
1% Triton X-100, 1 mM PMSF, 1 mM Na3VO4, and protease 
inhibitor cocktail (Roche Molecular Biochemicals, Indianapolis, 
IN, USA)]. Fractionation was performed by sequential extrac-
tion of cytosolic and nuclear proteins in non-ionic detergent 
for analysis of β-catenin. The same amount of protein was 
boiled at 95˚C after adding SDS sample buffer [62.5 mM 
Tris-Cl (pH 6.8), 2% sodium dodecyl sulfate, 10% glycerol, 
β-mercaptoethanol, and 0.002% bromophenol blue]. Samples 
were loaded on 8% SDS-PAGE gels for DAPK1 and FAK and 
on 10% SDS-PAGE gels for DAPK2 analyses and transferred 
to PVDF membranes (Amersham Biosciences, Pisctaway, NJ, 
USA). Anti-DAPK1 (Santa Cruz Biotechnology, Santa Cruz, 
CA, USA), Anti-DAPK2 (Santa Cruz Biotechnology), and 
anti-FAK (Santa Cruz Biotechnology) were used as the primary 
labeling antibodies, and the appropriate horseradish peroxidase-
conjugated antibodies (Santa Cruz Biotechnology) were used 
as secondary antibodies. An enhanced chemiluminescence 
detection system (ECL-Plus, Intron, Seoul, Korea) was used for 
detection according to the manufacturer's protocol.
Immunofluorescence microscopy. Human gastric cancer cells 
were cultured on chamber slides and then washed with phos-
phate-buffered saline (PBS) and fixed with 10% formaldehyde. 
They were then incubated with anti-DAPK1, anti-DAPK2, 
and anti-FAK antibodies and stained with anti-goat IgG-FITC 
and anti-rabbit IgG-FITC antibodies (all from Santa Cruz 
Biotechnology). Cells were visualized using a Zeiss LSM 510 
confocal laser-scanning microscope (Carl Zeiss, USA).
Flow cytometry. Human gastric cancer cells were treated 
with 2 µM NaB, 2 µM 5'-Aza-dC for 48 h, replacing the drug 
and medium every 24 h. Prepared cells were harvested after 
washing with PBS. Collected cells were lysed with 1X binding 
buffer (BD Biosciences, USA). One hundred microliters of the 
lysate was transferred to a 5 ml culture tube and treated with 
FITC Annexin-V and PI (BD Biosciences) for 15 min at 25˚C 
in the dark. The cell cycle distribution was determined using a 
FACScan flow cytometer (Becton-Dickinson, Mountain View, 
CA, USA) and 10,000 cells were analyzed with the MultiCycle 
software package (Phoenix Flow Systems, San Diego, CA, 
USA).
Figure 1. Treatment with NaB inhibits human gastric cancer cell prolifera-
tion. Cells were seeded in 96-well plates. The colorimetric MTS assays were 
used to measure cell numbers at 48 h. Experiments were performed in tripli-
cates. NaB, sodium butyrate. 
Figure 2. Apoptosis induced by NaB. Cells were harvested and analysed 
48 h after treatment with sodium butyrate. Apoptotic cells are indicated as 
the sub-G1 fraction, and percentages are shown on the top. NaB, sodium 
butyrate.
Figure 3. Effect of NaB on gene expression by RT-PCR. Caspase-3, Bcl-2, 
DAPK1, DAPK2, DAPK3, p53 and p21 expression in the indicated human 
gastric cancer cell lines, with treatment of NaB, 5,-Aza-dC. RT-PCR for 
β-actin was carried out for all samples for control. NaB, sodium butyrate.
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Cell proliferation assay. Human gastric cancer cells were 
seeded in 96-well plates. Cells were treated with 2 µM NaB, 
2 µM 5'-Aza-dC and 200 nM trichostatin A for 48 h, replacing 
the drug and medium every 24 h. The colorimetric MTS 
(Promega) assay was used to measure cell numbers at 48 h, 
according to the manufacturer's manual. Experiments were 
performed in triplicate.
Results
Sodium butyrate inhibited cell proliferation. We examined 
the effects of NaB on human gastric cancer cell proliferation. 
After 48 h of NaB treatment, cell viability was reduced from 
0.58 to 0.41 in AGS, from 0.40 to 0.22 in MKN45, from 0.63 
to 0.34 in MKN74, from 0.66 to 0.39 in NCI-N87, from 1.2 to 
0.63 in SNU1, from 0.44 to 0.21 in SNU16, from 0.42 to 0.19 
in Kato Ⅲ, from 0.45 to 0.19 in MKN28, and from 0.99 to 0.45 
in SNU638 (all P<0.05) as determined by the cell proliferation 
assay (Fig. 1).
Sodium butyrate induced apoptosis of human gastric cancer 
cells. Cell apoptosis was determined by counting sub-G1 
phase cells with flow cytometry analysis. After 48 h of NaB 
treatment, cell apoptosis significantly increased from 0.05 
to 7.2% in AGS and from 0.07 to 5.83% in MKN45 (both 
P<0.05). These findings suggested that NaB induced cell 
apoptosis (Fig. 2).
Effect of sodium butyrate on apoptosis-regulated protein 
expression. Sodium butyrate increased the expression of 
caspase-3, DAPK1, and DAPK2 but decreased the expression 
of Bcl-2 in both AGS and MKN45 cells. The expression of 
DAPK3, p53 and p21 genes was not altered by NaB treatment 
(Fig. 3). These finding suggests that NaB induces DAPK1/2 
expression in human gastric cancer cells.
Sodium butyrate increased DAPKs expression and decreased 
the expression of FAK in human gastric cancer cells. To 
confirm DAPKs expression induced by NaB treatment, Western 
blot analysis was performed 48 h after treatment with NaB. 
Expression of DAPK1/2 was increased, while that of FAK was 
decreased in human gastric cancer cells (Fig. 4). These finding 
suggest that NaB induced the expression of DAPK1/2, leading 
to decreased protein levels of FAK, prompting cell apoptosis.
Increased DAPKs expression and decreased FAKs expres-
sion induced by sodium butyrate treatment demonstrated by 
immunofluorescence. To confirm DAPKs expression induced 
by NaB, an immunofluorescence assay was analyzed 48 h after 
treatment of cells with NaB. Sodium butyrate increased the 
expression of the DAPK1/2 protein but decreased the expres-
sion of FAK. These findings suggest that NaB induced the 
Figure 4. Effect of NaB on the protein level of DAPK1, DAPK2, FAK in 
human gastric cancer cell lines. The loading and transfer of equal amounts 
of protein were confirmed by immunodetection of β-actin. NaB, sodium 
butyrate.
Figure 5. Increased DAPK1/2 expression by butyrate treatment in human gastric cell lines. Immunofluorescence assay of the intracellular distribution DAPK1/2 
in human gastric cell lines (A and B). Cells were stained with anti-DAPK1/2 antibody (green). Nuclei were visualized using 4',6-diamidino-2-phenylindole 
(DAPI, blue).
  A   B
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expression of DAPK1/2, leading to decreased protein levels of 
FAK (Figs. 5 and 6).
Discussion
Sodium butyrate enhances the response of chemotherapeutic 
agents in human gastric cancer cells (13-15). Consistent with 
previous studies, we have confirmed that sodium butyrate can 
induce demethylation of the SFRP gene promoter. HDAC 
inhibitors are capable of inducing apoptosis and cell cycle 
arrest at the G1/G2 phase by altering gene expression (16-23).
In the current study, we aimed to assess sodium butyrate-
induced death-associated protein kinase expression, which 
promotes human gastric cancer cell apoptosis. We first sought 
to assess the role of sodium butyrate in human gastric cancer 
cells using several independent approaches. Our results suggest 
that sodium butyrate inhibits cell proliferation and induces 
cell apoptosis in human gastric cancer cells.
The level of caspase-3 mRNA expression increased in 
human gastric cancer cells following treatment with sodium 
butyrate. Although no studies support the fact that the tran-
scription of caspase-3 can be upregulated directly by histone 
acetylation, recent evidence suggests that HDAC inhibitors 
also enhance the acetylation of non-histone proteins (24,25). 
Down-regulation of Bcl-2 was present after 48 h of exposure 
to sodium butyrate. These findings suggest that caspase-3 
was increased by sodium butyrate in human gastric cancer 
cells, but not Bcl-2. The p53 gene is not involved in butyrate-
induced growth inhibition of breast cancer cells (26). The 
current study also demonstrates that sodium butyrate did not 
induce p53 or p21 expression. Recently, it has been reported 
that the histone deacetylase inhibitor, TSA, could induce cells 
to express DAPK and promote cell apoptosis (24). DAPK 
expression causes tumor cells to lose sensitivity to anoikis, 
enabling anchor-independent survival of tumor cells (25). 
Our results found that DAPK1/2, but not DAPK3, expres-
sion was increased by sodium butyrate treatment in human 
gastric cancer cells. DAPK1/2 is responsible for the induction 
of apoptosis, while DAPK3 usually induces morphological 
changes in apoptosis.
FAK is involved in adhesion between cells and the extra-
cellular matrix, and joins cytoskeletal proteins. FAK is a 
survival protein that suppresses apoptosis (23). Our experi-
ments demonstrate that sodium butyrate induced DAPK1/2 
expression but down-regulated FAK expression in human 
gastric cancer cells. These findings suggest that a sodium 
butyrate-induced DAPK-dependent decrease in FAK via 
the caspase-dependent pathway leads to apoptosis in human 
gastric cancer cells. In conclusion, sodium butyrate induced 
DAPK expression in human gastric cancer cells and this 
expression prompted apoptosis by decreasing FAK levels.
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